Applied Therapeutics, Inc. announced promising 18 and 24-month results from the INSPIRE Phase 2/3 trial of govorestat, a treatment for Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results